Latest Oncology Stories
Activity with VAL-083 Observed in Recurrent Malignant Glioma and Progressive Secondary Brain Tumors VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced that the company presented a poster entitled "Phase I/II Study of VAL-083 (dianhydrogalactitol) in Patients with Recurrent Malignant Glioma or Progressive Secondary Brain Tumor" at the American Society of Clinical Oncology (ASCO) Annual...
CHICAGO, June 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced results from its PRONOUNCE trial of ALIMTA® (pemetrexed for injection) for treatment of nonsquamous non-small cell lung cancer (NSCLC) that was presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill. The PRONOUNCE trial compared an ALIMTA (pemetrexed), carboplatin doublet regimen to a paclitaxel, carboplatin and bevacizumab triplet regimen. The study did...
PRINCETON, N.J., June 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients has received "Fast Track" designation from the US Food and Drug Administration (FDA). Fast track is a designation that the FDA reserves for a drug intended to...
Previstage(TM )GCC colorectal cancer test featured at the 2013 ASCO Annual Meeting QUEBEC CITY, June 3, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) today reported that results of a new study were presented on Sunday, June 2, during the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois. The abstract of the presentation entitled "Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in...
New trial results presented at American Society of Clinical Oncology (ASCO) 2013 represent first advance in almost a decade in overall survival for patients where initial chemotherapy has failed BURLINGTON, ON, June 3, 2013 /CNW/ - New research on Canada's number one cancer killer(1) is further proof that patients need personalized treatments targeted to their specific type of lung cancer for better outcomes. Boehringer Ingelheim (Canada) Ltd. today announced highly anticipated...
Test Validated by Largest Melanoma Biomarker Program of its Kind Data Being Presented at American Society of Clinical Oncology Annual Meeting FRIENDSWOOD, Texas, June 3, 2013 /PRNewswire/ -- Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #9022). Results show that the gene expression profile test strongly predicts...
Lee National Denim Day® set to raise millions for breast cancer research and community-based programs in 2013 MERRIAM, Kan., June 3, 2013 /PRNewswire/ -- On the heels of National Cancer Survivors Day, Lee Jeans is proud to name Amy, a Kansas City resident currently fighting breast cancer, the 2013 Lee National Denim Day ambassador. On Friday, October 4, millions will join the Lee National Denim Day movement by putting on their jeans and donating $5 to raise millions of dollars for...
The Pancreas Cancer Research Team (PCRT) is the world’s only program dedicated to rapidly translating research discoveries into new treatments and supportive care for patients with pancreas cancer. SCOTTSDALE, Ariz. (PRWEB) June 01, 2013 Ten years after its founding, the Pancreatic Cancer Research Team (PCRT) is announcing the positive results of a large Phase III clinical trial involving more than 800 patients. PCRT is celebrating its 10th anniversary of accelerating new and effective...
Voices Against Brain Cancer comments on a potential new target that gives promise for treating glioblastomas. New York, NY (PRWEB) June 01, 2013 On June 1, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a possible new target that may enhance brain cancer treatment. According to a Futurity.org article, researchers are working on targeting a specific enzyme that may be able to inhibit and kill glioblastoma cells and other forms of...
Mount Sinai researchers to present landmark studies at American Society of Clinical Oncology meeting. New York, NY (PRWEB) June 01, 2013 Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2013 American Society of Clinical Oncology (ASCO) meeting May 31-June 4, 2013 in Chicago, including data on the likelihood of spousal human papillomavirus (HPV) oral infection, new gene signatures in melanoma, and issues with high readmission rates after...
